Study details
A study on the treatment of immune thrombocytopenia.
Title: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study Followed by an Open-Label Arm to Evaluate the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia.
ClinicalTrials.gov ID:
NCT06544499
Principal Investigator:
prof. Marta Sobas, MD, PhD
Study description
Recruitment status: Open
Study phase: Phase 3
Simplified inclusion criteria:
• Newly diagnosed multiple myeloma (note: likely inconsistency in original text)
• Good performance status (ECOG 0–2)
Simplified exclusion criteria:
• Patients classified as frail
Contact
Clinical trial coordinator
Justyna Korzenecka
e-mail: justyna.korzenecka@cm.umk.pl